| 1 |
Mirza R, Koh TJ. Dysregulation of monocyte/macrophage phenotype in wounds of diabetic mice[J]. Cytokine, 2011, 56(2): 256-264.
|
| 2 |
Bitto A, Altavilla D, Pizzino G, et al. Inhibition of inflammasome activation improves the impaired pattern of healing in genetically diabetic mice[J]. Br J Pharmacol, 2014, 171(9): 2300-2307.
|
| 3 |
Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta[J]. Mol Cell, 2002, 10(2): 417-426.
|
| 4 |
Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation[J]. Nat Rev Mol Cell Biol, 2003, 4(2): 95-104.
|
| 5 |
Artlett CM. The Role of the NLRP3 Inflammasome in Fibrosis[J]. Open Rheumatol J, 2012, 6: 80-86.
|
| 6 |
Mcneela EA, Burke A, Neill D R, et al. Pneumolysin activates the NLRP3 inflammasome and promotes proinflammatory cytokines independently of TLR4[J]. PLoS Pathog, 2010, 6(11): e1001191.
|
| 7 |
Mori MA, Bezy O, Kahn CR. Metabolic syndrome: is Nlrp3 inflammasome a trigger or a target of insulin resistance[J]. Circ Res, 2011, 108(10): 1160-1162.
|
| 8 |
Franchi L, Mcdonald C, Kanneganti TD, et al. Nucleotide-binding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense[J]. J Immunol, 2006, 177(6): 3507-3513.
|
| 9 |
Franchi L, Eigenbrod T, Muñoz-Planillo R, et al. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis[J]. Nat Immunol, 2009, 10(3): 241-247.
|
| 10 |
Kanneganti TD. Central roles of NLRs and inflammasomes in viral infection[J]. Nat Rev Immunol, 2010, 10(10): 688-698.
|
| 11 |
Lamkanfi M, Dixit VM. Inflammasomes: guardians of cytosolic sanctity[J]. Immunol Rev, 2009, 227(1): 95-105.
|
| 12 |
Schroder K, Tschopp J. The inflammasomes[J]. Cell, 2010, 140(6): 821-832.
|
| 13 |
Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes[J]. Cell, 2014, 157(5): 1013-1022.
|
| 14 |
Lu A, Magupalli VG, Ruan J, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes[J]. Cell, 2014, 156(6): 1193-1206.
|
| 15 |
Cai X, Chen J, Xu H, et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation[J]. Cell, 2014, 156(6): 1207-1222.
|
| 16 |
Taniguchi S, Sagara J. Regulatory molecules involved in inflammasome formation with special reference to a key mediator protein, ASC[J]. Semin Immunopathol, 2007, 29(3): 231-238.
|
| 17 |
Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance[J]. Nat Med, 2011, 17(2): 179-188.
|
| 18 |
Vanaja SK, Rathinam VA, Fitzgerald KA. Mechanisms of inflammasome activation: recent advances and novel insights[J]. Trends Cell Biol, 2015, 25(5): 308-315.
|
| 19 |
Jin C, Flavell RA. Molecular mechanism of NLRP3 inflammasome activation[J]. J Clin Immunol, 2010, 30(5): 628-631.
|
| 20 |
Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome[J]. J Cell Biol, 2009, 187(1): 61-70.
|
| 21 |
Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization[J]. Nat Immunol, 2008, 9(8): 847-856.
|
| 22 |
Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger[J]. Science, 2010, 327(5963): 296-300.
|
| 23 |
Lee MS. Role of innate immunity in diabetes and metabolism: recent progress in the study of inflammasomes[J]. Immune Netw, 2011, 11(2): 95-99.
|
| 24 |
Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production[J]. Nat Rev Immunol, 2010, 10(3): 210-215.
|
| 25 |
Rathinam VA, Vanaja SK, Fitzgerald KA. Regulation of inflammasome signaling[J]. Nat Immunol, 2012, 13(4): 333-342.
|
| 26 |
Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptor-associated inflammasome activation[J]. Immunity, 2013, 39(3): 432-441.
|
| 27 |
Menu P, Mayor A, Zhou R, et al. ER stress activates the NLRP3 inflammasome via an UPR-independent pathway[J]. Cell Death Dis, 2012, 3: e261.
|
| 28 |
Diao L, Marshall AH, Dai X, et al. Burn plus lipopolysaccharide augments endoplasmic reticulum stress and NLRP3 inflammasome activation and reduces PGC-1alpha in liver[J]. Shock, 2014, 41(2): 138-144.
|
| 29 |
Lerner AG, Upton JP, Praveen PV, et al. IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress[J]. Cell Metab, 2012, 16(2): 250-264.
|
| 30 |
Bauernfeind F, Bartok E, Rieger A, et al. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome[J]. J Immunol, 2011, 187(2): 613-617.
|
| 31 |
Fernandes-Alnemri T, Kang S, Anderson C, et al. Cutting edge: TLR signaling licenses IRAK1 for rapid activation of the NLRP3 inflammasome[J]. J Immunol, 2013, 191(8): 3995-3999.
|
| 32 |
Juliana C, Fernandes-Alnemri T, Kang S, et al. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation[J]. J Biol Chem, 2012, 287(43): 36617-36622.
|
| 33 |
Schroder K, Sagulenko V, Zamoshnikova A, et al. Acute lipopolysaccharide priming boosts inflammasome activation independently of inflammasome sensor induction[J]. Immunobiology, 2012, 217(12): 1325-1329.
|
| 34 |
Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease[J]. Annu Rev Cell Dev Biol, 2012, 28: 137-161.
|
| 35 |
Ozaki E, Campbell M, Doyle SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives[J]. J Inflamm Res, 2015, 8: 15-27.
|
| 36 |
Simard JC, Cesaro A, Chapeton-Montes J, et al. S100A8 and S100A9 induce cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent activation of NF-kappaB(1.)[J]. PLoS One, 2013, 8(8): e72138.
|
| 37 |
Luo B, Li B, Wang W, et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model[J]. PLoS One, 2014, 9(8): e104771.
|
| 38 |
Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation[J]. Nat Immunol, 2010, 11(2): 136-140.
|
| 39 |
Collier JJ, Burke SJ, Eisenhauer ME, et al. Pancreatic beta-cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis[J]. PLoS One, 2011, 6(7): e22485.
|
| 40 |
Osborn O, Brownell SE, Sanchez-Alavez M, et al. Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity[J]. Cytokine, 2008, 44(1): 141-148.
|
| 41 |
Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling[J]. Nat Immunol, 2011, 12(5): 408-415.
|
| 42 |
Singer AJ, Clark RA. Cutaneous wound healing[J]. N Engl J Med, 1999, 341(10): 738-746.
|
| 43 |
Nishigaki A. [Experimental studies of skin wound healing process by first intention in streptozotocin-induced diabetes mellitus rats][J]. Shikwa Gakuho, 1989, 89(4): 793-822.
|
| 44 |
Blakytny R, Jude E. The molecular biology of chronic wounds and delayed healing in diabetes[J]. Diabet Med, 2006, 23(6): 594-608.
|
| 45 |
Mirza R, Dipietro LA, Koh TJ. Selective and specific macrophage ablation is detrimental to wound healing in mice[J]. Am J Pathol, 2009, 175(6): 2454-2462.
|
| 46 |
崔胜勇，刘琰，章雄. 巨噬细胞功能障碍与糖尿病慢性难愈创面的关系[J]. 中华烧伤杂志，2014, 30(3): 264-269.
|
| 47 |
Lucas T, Waisman A, Ranjan R, et al. Differential roles of macrophages in diverse phases of skin repair[J]. J Immunol, 2010, 184(7): 3964-3977.
|
| 48 |
Daley JM, Brancato SK, Thomay AA, et al. The phenotype of murine wound macrophages[J]. J Leukoc Biol, 2010, 87(1): 59-67.
|
| 49 |
Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation[J]. Nat Rev Immunol, 2008, 8(12): 958-969.
|
| 50 |
Okizaki S, Ito Y, Hosono K, et al. Suppressed recruitment of alternatively activated macrophages reduces TGF-beta1 and impairs wound healing in streptozotocin-induced diabetic mice[J]. Biomed Pharmacother, 2015, 70: 317-325.
|
| 51 |
Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases[J]. Blood, 2011, 117(14): 3720-3732.
|
| 52 |
Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family[J]. Annu Rev Immunol, 2009, 27: 519-550.
|
| 53 |
Mirza RE, Fang MM, Ennis WJ, et al. Blocking interleukin-1beta induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes[J]. Diabetes, 2013, 62(7): 2579-2587.
|
| 54 |
Mirza RE, Fang MM, Weinheimer-Haus EM, et al. Sustained inflammasome activity in macrophages impairs wound healing in type 2 diabetic humans and mice[J]. Diabetes, 2014, 63(3): 1103-1114.
|